Related Experiment Video
Updated: Jul 14, 2026

A Photopolymerizable Hyaluronic Acid-Collagen Model of the Invasive Glioma Microenvironment with Interstitial Flow
Published on: October 18, 2024
Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas
Valeria Barresi1, Serenella Cerasoli, Enrica Vitarelli
1Dipartimento di Patologia Umana, University of Messina, Messina, Italy. valeriabarresi@hotmail.com
Abstract:
Microvessel density (MVD) is considered to be a prognostic marker in many tumours. Nevertheless, conflicting results were achieved regarding its prognostic role in meningiomas when it was quantified through pan-endothelial markers such as CD34, CD31 or Factor VIII. In the present study, MVD was assessed in meningiomas through the specific marker for neo-angiogenesis CD105. Fifty-four formalin fixed, paraffin embedded, surgical cases of meningiomas (WHO 28 grade I and 26 grade II) as well as ten normal leptomeningeal samples were submitted to immunohistochemical analysis for CD105. CD34 immuno-expression was also evaluated on consecutive parallel sections. For each case, MVD was estimated in terms of number of vessels/mm(2). CD105 was not evidenced in normal samples, whereas it was demonstrated in the vessels within 14/28 WHO grade I cases and within 24/26 WHO grade II meningiomas. On the contrary, CD34 antibody stained blood vessels in both normal and neoplastic samples; moreover, in each case, it stained more microvessels than CD105 antibody (25.33 +/- 21.16 vs. 50.72 +/- 26.75). Higher CD105 counts were significantly correlated with higher histological grade and Ki-67 LI > 4%. No statistical significant correlations were encountered between MVD measured by either CD105 and CD34 and sex, age, site of tumour or extent of surgical resection. CD105-MVD, but not CD34-MVD, showed an inverse significant correlation with overall survival and recurrence-free survival. In conclusion, our study suggests the higher specificity of CD105 in comparison to pan-endothelial markers in the evaluation of meningioma neo-angiogenesis, and its higher prognostic significance. CD105 might serve as a target for therapeutic approaches blocking blood supply in meningiomas.
Insights
This study shows that CD105 is a more specific marker for assessing neo-angiogenesis in meningiomas than CD34. Higher CD105 levels correlate with tumor grade and predict survival, suggesting it as a therapeutic target.
Area of Science:
- Neuro-oncology
- Tumor Angiogenesis
- Immunohistochemistry
Background:
- Microvessel density (MVD) is a prognostic marker in many tumors, but its role in meningiomas is debated when using pan-endothelial markers.
- Previous studies using markers like CD34 yielded conflicting results regarding MVD's prognostic value in meningiomas.
Purpose of the Study:
- To assess microvessel density (MVD) in meningiomas using the specific neo-angiogenesis marker CD105.
- To compare the prognostic significance of CD105-assessed MVD with CD34-assessed MVD in meningiomas.
- To evaluate CD105 as a potential therapeutic target for meningioma treatment.
Main Methods:
- Immunohistochemical analysis of CD105 and CD34 on 54 meningioma samples (28 WHO grade I, 26 WHO grade II) and 10 normal leptomeningeal samples.
- Quantification of MVD as the number of vessels per mm² for both CD105 and CD34.
- Correlation analysis between MVD, histological grade, Ki-67 labeling index, patient demographics, and survival outcomes.
Main Results:
- CD105 was absent in normal meninges but present in 14/28 grade I and 24/26 grade II meningiomas.
- CD34 stained more microvessels than CD105 in all samples (50.72 vs. 25.33 vessels/mm²).
- Higher CD105 counts correlated significantly with higher tumor grade and Ki-67 LI (>4%).
- CD105-MVD, unlike CD34-MVD, showed a significant inverse correlation with overall survival and recurrence-free survival.
Conclusions:
- CD105 is a more specific marker for evaluating neo-angiogenesis in meningiomas compared to pan-endothelial markers like CD34.
- CD105-assessed MVD has greater prognostic significance in meningiomas.
- CD105 may represent a promising therapeutic target for blocking blood supply in meningiomas.
